Binod Dhakal, MD

Articles

Dr Dhakal on Notable Multiple Myeloma Trials Presented in 2024

October 29th 2024

Binod Dhakal, MD, discusses key trials presented at the 21st International Myeloma Society Annual Meeting in patients with multiple myeloma.

Dr Dhakal on the Design of the CARTITUDE-4 Study in R/R Myeloma

October 23rd 2024

Binod Dhakal, MD, discusses the design of the CARTITUDE-4 study investigating cilta-cel in relapsed/refractory multiple myeloma.

Dr Dhakal on Survival and Safety Outcomes With Cilta-Cel in R/R Myeloma

October 2nd 2024

Binod Dhakal, MD, discusses survival data with ciltacabtagene autoleucel in lenalidomide-refractory relapsed/refractory multiple myeloma.

Dr. Dhakal on the Mechanism of Action of Orva-Cel in Multiple Myeloma

February 26th 2021

Binod Dhakal, MD, discusses the mechanism of action of orvacabtagene autoleucel in multiple myeloma.

Dr. Dhakal on Responses Achieved With Orva-Cel in Multiple Myeloma

February 16th 2021

Binod Dhakal, MD, discusses responses achieved with orvacabtagene autoleucel in patients with multiple myeloma.

Dr. Dhakal on the Onset of CAR T-Cell Therapy–Induced CRS in Multiple Myeloma

February 3rd 2021

Binod Dhakal, MD, discusses the differences in onset of cytokine release syndrome with CAR T-cell therapies in multiple myeloma.

Dr. Dhakal on Early Data With BiTEs in Multiple Myeloma

May 3rd 2019

Binod Dhakal, MD, assistant professor, Medical College of Wisconsin, discusses early data with bispecific T-cell engager (BiTE) antibody constructs in multiple myeloma.